Onyx™ Liquid Embolic IDE klinisk undersøgelse
PELE IDE klinisk undersøgelse, Perifer Onyx™ væskeembolisk sikkerhed og effektiviteten af Onyx™ LES til embolisering af arteriel blødning i den perifere vaskulatur
The purpose of this study is to evaluate the safety and effectiveness of Onyx™ LES in the treatment of subjects with active arterial bleeding in the peripheral vasculature outside of the heart and brain.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
This is a pivotal, prospective, multi-center, non-randomized, single arm study. This study will enroll patients with active arterial bleeding in the peripheral vasculature confirmed by radiologic and/or endoscopic imaging and deemed suitable for embolization treatment by investigator. In this study, peripheral vasculature is defined as outside of the brain and heart.
Approximately 135 subjects will be consented to achieve 119 enrolled at up to 25 sites in the US.
This study will have two visits post-index procedure including hospital discharge visit and 30-day follow-up visit. Reintervention visits will be captured through 30 days post-index procedure.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Liza Marie
- Telefonnummer: 7072172314
- E-mail: liza.marie@medtronic.com
Undersøgelse Kontakt Backup
- Navn: Janki Shah
- Telefonnummer: 7322662503
- E-mail: janki.shah@medtronic.com
Studiesteder
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85054
- Rekruttering
- Mayo Clinic
-
Kontakt:
- Debbie Ryan
- Telefonnummer: 480-342-1208
- E-mail: ryan.debra29@mayo.edu
-
Ledende efterforsker:
- Sadeer Alzubaidi, MD
-
Kontakt:
- Yahaira Parker
-
-
California
-
Irvine, California, Forenede Stater, 92627
- Rekruttering
- University of California, Irvine
-
Kontakt:
- Nadine Jaoudeh, MD
- E-mail: nadine@hs.uci.edu
-
Kontakt:
- Kimberly Padilla
- E-mail: kpadill6@hs.uci.edu
-
Los Angeles, California, Forenede Stater, 90095
- Rekruttering
- University of California Los Angeles
-
Kontakt:
- Renato Escobar
- E-mail: raescobar@mednet.ucla.edu
-
Ledende efterforsker:
- Jessica Stewart, MD
-
Palo Alto, California, Forenede Stater, 94304
- Rekruttering
- Stanford Medical Center
-
Kontakt:
- Andrew Picel, MD
-
Kontakt:
- Abigail Bond
- E-mail: abond02@stanford.edu
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- Rekruttering
- UCHealth University of Colorado Hospital
-
Kontakt:
- Alejandra Aguilar, MPH
- E-mail: alejandra.aguilar@cuanschutz.edu
-
Ledende efterforsker:
- Eduardo Bent Robinson, MD
-
-
Connecticut
-
New Haven, Connecticut, Forenede Stater, 06510
- Rekruttering
- Yale New Haven
-
Kontakt:
- Patricia Fugal
- E-mail: patricia.fugal@yale.edu
-
Kontakt:
- Angelo Marino, MD
- E-mail: angelo.marino@yale.edu
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60637
- Rekruttering
- University of Chicago
-
Kontakt:
- Tiana Jackson
- E-mail: tiana.jackson@bsd.uchicago.edu
-
Ledende efterforsker:
- Brian Funaki, MD
-
-
Iowa
-
Iowa City, Iowa, Forenede Stater, 52242
- Rekruttering
- University of Iowa Hospitals and Clinics
-
Ledende efterforsker:
- Michael Hummel, MD
-
Kontakt:
- Victoria Mendoza
- E-mail: victoria-mendoza@uiowa.edu
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02114
- Rekruttering
- Masschusetts General Hospital
-
Kontakt:
- Vincent Wu, MD
- E-mail: vwu3@mgh.harvard.edu
-
Kontakt:
- Justin Hill
- E-mail: jhill43@mgh.harvard.edu
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68124
- Rekruttering
- CHI Health Creighton University Medical Center-Bergan-Mercy
-
Kontakt:
- Janice Mitchel
- Telefonnummer: 402-619-9402
- E-mail: jan.mitchell@commonspirit.org
-
Ledende efterforsker:
- Patrick Harty
-
-
New Jersey
-
Newark, New Jersey, Forenede Stater, 07103
- Rekruttering
- Rutgers New Jersey Medical School
-
Ledende efterforsker:
- Abhishek Kumar, MD
-
Kontakt:
- Saharsh Patel
- E-mail: ssp186@gsbs.rutgers.edu
-
-
New York
-
Albany, New York, Forenede Stater, 12208
- Rekruttering
- Albany Medical Center
-
Kontakt:
- Nancy Spencer, NP
- E-mail: spencen@amc.edu
-
Kontakt:
- Gary Siskin, MD
- E-mail: sisking@amc.edu
-
New York, New York, Forenede Stater, 10029
- Rekruttering
- The Mount Sinai
-
Kontakt:
- Rajesh Patel, MD
- E-mail: rajesh.patel@mountsinai.org
-
Kontakt:
- Aaron Greenberg
- E-mail: aaron.greenberg@mountsinai.org
-
-
North Carolina
-
Chapel Hill, North Carolina, Forenede Stater, 27599
- Rekruttering
- University of North Carolina at Chapel Hill
-
Ledende efterforsker:
- Nima Kokabi, MD
-
Kontakt:
- Adriana Delgado
- E-mail: adriana_delgado@med.unc.edu
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44106
- Rekruttering
- University Hospitals Cleveland Medical Center
-
Kontakt:
- Lauren Hahn
- E-mail: lauren.hahn@uhhospitals.org
-
Ledende efterforsker:
- Salim Abboud, MD
-
Columbus, Ohio, Forenede Stater, 43210
- Rekruttering
- The Ohio State University
-
Kontakt:
- Mina Makary, MD
-
Kontakt:
- Gage Spears
- E-mail: gage.spears@osumc.edu
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forenede Stater, 15237
- Rekruttering
- University of Pittsburgh Medical Center
-
Ledende efterforsker:
- Paula Novelli, MD
-
Kontakt:
- Suzanne Burdin
- E-mail: burdins@upmc.edu
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37212
- Rekruttering
- Vanderbilt University Medical Center
-
Kontakt:
- Celia Nunez
- Telefonnummer: 615-322-4559
- E-mail: celia.m.nunez@vumc.org
-
Ledende efterforsker:
- Anthony Borgmann, MD
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75235
- Rekruttering
- Univ Of Texas Southwestern
-
Ledende efterforsker:
- Sanjeeva Kalva, MD
-
Kontakt:
- Camille Harry
- Telefonnummer: 214-648-8986
- E-mail: camille.harry@utsouthwestern.edu
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- The University of Texas Health Science Center at Houston
-
Kontakt:
- Praneeth Nadimpalli
- E-mail: praneeth.v.nadimpalli@uth.tmc.edu
-
Kontakt:
- Lauren McGuire, RN
- E-mail: lauren.c.mcguire@uth.tmc.edu
-
Ledende efterforsker:
- Rodrick Zvavanjanja, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Patient is ≥ 22 years old.
-
Active arterial bleeding in the peripheral vasculature confirmed by radiologic and/or endoscopic imaging and deemed suitable for embolization treatment by the investigator.
In this study, peripheral vasculature is defined as outside the brain and heart.
-
Patient or legally authorized representative (LAR) is able to provide written consent to participate in the study.
-
Life expectancy of >30 days, in the opinion of the investigator at the time of enrollment.
-
Target treatment area is free from prior embolization treatment.
Exclusion Criteria:
- Pregnant or breastfeeding.
- Symptoms of active infection.
- Patient is known to be participating in the study of an investigational drug, biologic, or device.
- Contrast allergy or other contraindication to angiography, CT, or catheterization, including contrast sensitivity that cannot be adequately treated prior to index procedure.
- Known allergy to components of Onyx™.
- Target vasculature unsuitable for the delivery of Onyx™ based upon physician assessment.
- More than 4 target lesions will require embolization, in the investigator's opinion after imaging-based assessment.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Treatment with Onyx LES
Device; embolization with liquid embolic |
The proposed indication for Onyx™ LES is: Onyx™ LES is indicated for the embolization of arterial hemorrhage in the peripheral vasculature.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Freedom from Arterial Hemorrhage
Tidsramme: Through 30 days post-index procedure
|
Freedom from arterial hemorrhage in all target location(s) after treatment with Onyx™ LES at the index procedure without re-embolization or any other intervention at the target location(s) due to persistent or recurrent hemorrhage through 30 days. Freedom from arterial hemorrhage where an arterial hemorrhage event is defined as a type 3 or greater BARC bleeding criteria as assessed by the Clinical Events Committee (CEC) through 30 days. |
Through 30 days post-index procedure
|
|
Freedom from System-related Major Adverse Events (MAE)
Tidsramme: Through 30 days post-index procedure
|
The primary safety endpoint is defined as freedom from system-related Major Adverse Events (MAE) through 30 days after the point of enrollment as assessed by the CEC. |
Through 30 days post-index procedure
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Procedural Success
Tidsramme: At the completion of the index procedure
|
successful delivery and deployment of Onyx™ to the target location without non-target embolization or Onyx™ cast migration and the successful removal of the delivery system at the completion of the index procedure. |
At the completion of the index procedure
|
|
Technical Success
Tidsramme: At the completion of the index procedure
|
Technical Success is defined as absence of angiographic signs of bleeding after Onyx ™ embolization at each target location based on core lab assessment. |
At the completion of the index procedure
|
|
Reintervention
Tidsramme: Through 30 days post-index procedure
|
Reintervention is defined as the number of additional procedures needed to treat the target location(s) embolized with Onyx™ through 30 days following the index procedure. |
Through 30 days post-index procedure
|
|
Transfusions
Tidsramme: Through 30 days post-index procedure
|
Transfusions defined as the number of blood transfusions required post-index procedure through 30 days will use blood transfusions starting after the removal of the delivery system. The number of blood units used for each transfusion will also be collected. |
Through 30 days post-index procedure
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Ancillary Endpoint
Tidsramme: Through index procedure
|
Duration of the index procedure |
Through index procedure
|
|
Ancillary Endpoint
Tidsramme: Through 30 days post-index procedure
|
Length of hospitalization, post-index procedure |
Through 30 days post-index procedure
|
|
Ancillary Endpoint
Tidsramme: Through 30 days post-index procedure
|
Tabulate adjunctive use of other types of embolic agents to treat target locations at index procedure and reinterventions |
Through 30 days post-index procedure
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Osman Ahmed, MD, University of Chicago
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- MDT21044
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .